US slashes 36% off Medicare spending on 15 high-priced medicines

Medicare announced new 2027 negotiated prices for 15 high-cost drugs that it says will lower net covered prescription spending by 36%, or about $8.5 billion, versus recent annual spending. Notable cuts include a $274 monthly price for Novo Nordisk’s semaglutide (Wegovy/Ozempic) versus Medicare’s recent net of $428 and list of $959, Trelegy set at $175 (vs $654 list), and Linzess at $136 (vs $539); AstraZeneca’s Calquence, Boehringer’s Ofev and Pfizer’s Ibrance each face cuts exceeding $4,000 from estimated net prices. The changes stem from negotiated pricing authority under the 2022 Inflation Reduction Act and signal a material revenue headwind for affected drugmakers while potentially setting price precedents for other payers and comparisons with international pricing.

Analysis

Market structure: Medicare price-setting directly redistributes economic surplus from large branded biopharma (notably AZN, PFE, ABBV, GSK) to payers and patients; Reuters' 36% average cut (~$8.5bn) and semaglutide dropping from ~$428 to $274/month implies mid-single-digit percentage hits to top-line for affected franchises in 2027, with outsized EPS sensitivity for single-product names. Competitive dynamics favor PBMs, Medicare Advantage insurers and lower-cost therapeutic alternatives; manufacturers lose pricing power but may offset via volume, indication expansion or higher list prices on unconstrained products.

Risk assessment: Tail risks include accelerated MFN or tougher next-round negotiations (Feb list) that deepen cuts >50% for some molecules, legal/legislative reversals, or a pharma pullback in R&D leading to multi-year innovation slowdowns; quantify downside: companies deriving >10% revenue from negotiated drugs could see 15–30% EBIT compression. Time buckets: equity reaction immediate (days–weeks), operational adjustments in 6–18 months, structural innovation impact over multiple years. Hidden: confidential rebates/net pricing mechanics mean headline list-price comparisons understate negotiated spillovers.

Trade implications: Tactical short exposure to names with largest announced cuts (AZN, PFE, ABBV) via 6–12 month put spreads to cap capital at 1–3% risk each; pair long payers (UNH 1–2%) versus short PFE/AZN to capture margin tailwind to insurers. Options: buy 9–12 month put spreads on AZN/PFE and buy 12–18 month call spreads on NVO (GLP-1 volume upside) size 1–2% each. Enter within 2–6 weeks ahead of Feb negotiations; trim positions after Feb list or any favorable court rulings.

Contrarian angles: Consensus underestimates volume elasticity for GLP‑1s — semaglutide unit demand could rise >30% post-cut, making NVO earnings resilient; conversely, market may over-discount drugs with diversified portfolios (PFE/AMGN) where negotiated items are <15% revenue. Historical EU price controls show price compression often drives mix-shifts not extinction of innovation; unintended consequence: firms re-route launches to non-Medicare segments or increase hospital-administered therapies, creating idiosyncratic winners. Act where market misprices volume-offset scenarios (select longs) and where single-product exposure is punished indiscriminately (shorts/hedges).

Key Decisions for Investors

• Establish a 2–3% portfolio short via 6–12 month put spreads on AstraZeneca (AZN) sized to risk 0.5–1% notional (target >15% downside) given Calquence >$4k monthly hit; use OTM puts ~7–12% strikes to limit premium outlay, enter within 2–4 weeks.
• Buy 9–12 month put spreads on Pfizer (PFE) and AbbVie (ABBV), each sized 1% portfolio risk, to hedge 2027 negotiated-price exposure; unwind if share price falls >15% or after Feb 2025 CMS negotiation announcements.
• Initiate a 1–2% long position in UnitedHealth (UNH) or Elevance (ELV) to capture payer margin tailwind from lower Medicare drug prices; target +8–12% outperformance in 6–12 months and take profits if realized PBM/payer guidance upgrades appear.
• Take a 1% contrarian long in Novo Nordisk (NVO) via 12–18 month call spreads (bull-call) anticipating GLP‑1 volume growth >30% offsets price cuts; scale in if NVO drops >8% or if quarterly volumes beat by >5% sequentially.
• If CMS legal/regulatory events accelerate (favorable court rulings or MFN pilot expansion) within next 3 months, increase short/put exposure by 50%; conversely, if court blocks enforcement, reallocate proceeds into large-cap diversified pharma (PFE, AMGN) and payers within 2 weeks of ruling.